文章摘要

纤溶酶原激活物抑制剂-1的研究进展

作者: 1蔡 雪蓉, 1张 学亚, 1潘 敬新
1 福建医科大学附属第二医院血液内科,福州 362000
通讯: 张 学亚 Email: jakey@sina.com
DOI: 10.3978/j.issn.2095-6959.2020.02.032
基金: 福建省母婴健康应用技术创新课题(XJM1805)。

摘要

纤溶酶原激活物抑制剂-1(plasminogen activator inhibitor 1,PAI-1)作为体内组织型纤溶酶原激活物(tissue-type plasminogen activator,t-PA)和尿激酶型纤溶酶原激活物(urokinase-type plasminogen activator,u-PA)的主要抑制剂,与动静脉血栓、出血和凝血异常、细胞迁移密切相关,进而引起缺血性脑卒中、冠心病、静脉血栓、肿瘤转移、出血、股骨头坏死、流产等一系列疾病的发生发展。同时,体内血浆PAI-1活性水平又受血脂、血糖等调节,进一步参与肥胖、糖尿病、高脂血症等疾病的进程,又影响着上述相关疾病的预后。
关键词: 纤溶酶原激活物抑制剂-1;组织型纤溶酶原激活物;尿激酶型纤溶酶原激活物;血栓;出血;肿瘤

Research progress in plasminogen activator inhibitor 1

Authors: 1CAI Xuerong, 1ZHANG Xueya, 1PAN Jingxin
1 Department of Hematology, Second Affiliated Hospital of Fujian Medical University, Fuzhou 362000, China

CorrespondingAuthor:ZHANG Xueya Email: jakey@sina.com

Foundation: This work was supported by the Fujian Province Maternal and Child Health Application Technology Innovation Project, China (XJM1805).

Abstract

Plasminogen activator inhibitor 1 (PAI-1), as the main inhibitor of tissue-type plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA) in body, is closely related to arteriovenous thrombosis, abnormal coagulation and cell migration, which further leads to the occurrence and development of a series of diseases including ischemic stroke, coronary heart disease, venous thrombosis, tumor metastasis, hemorrhage, femoral head necrosis and abortion. Meanwhile, the level of plasma PAI-1 in the body is regulated by blood lipids and blood glucose, which further involves obesity, diabetes, hyperlipidemia and other diseases, and affects the prognosis of the above-mentioned related diseases. PAI-1 research covers a wide range of areas.
Keywords: plasminogen activator inhibitor 1; tissue-type plasminogen activator; urokinase-type plasminogen activator; thrombus; bleeding; tumour